Dermatology Times, Horizons in Advanced Practice: Redefining Inflammatory Skin Disease Care, February 2026 (Vol. 47. Supp. 02)

Omar Noor, MD, FAAD, discusses strategies to improve psoriasis care for patients facing adherence challenges related to lifestyle or cognitive barriers.

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, reviewed clinical trial and long-term data supporting biologic therapies for HS, emphasizing individualized patient selection and timing of intervention.

Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed clinical cases highlighting the distinct roles of topical ruxolitinib, tapinarof, and roflumilast in managing itch, inflammation, and long-term disease control in atopic dermatitis.

Douglas DiRuggiero, DMSc, MHS, PA-C, emphasized that relying solely on body surface area underestimates psoriasis burden, particularly for patients with disease in high-impact or special areas.

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, highlighted that CHE is often mischaracterized and frequently involves overlapping subtypes.

Omar Noor, MD, shares pearls on type 2 inflammation, including dupilumab insights for atopic dermatitis, prurigo nodularis, and CSU at Horizons in Advanced Practice.

Dermatology Times recently concluded its second annual Horizons in Advanced Practice meeting in Tampa, Florida, featuring nurse practitioners and physician assistants from across the country.